Skip to main content

Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes

Medically reviewed by Carmen Pope, BPharm. Last updated on April 8, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 8, 2025 -- For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy (NAION), according to a study published online March 27 in JAMA Ophthalmology.

Alan Y. Hsu, M.D., from the China Medical University Hospital in Taichung City, Taiwan, and colleagues conducted a cohort study to examine the association between semaglutide use and risk for NAION among patients with diabetes. The semaglutide cohort was compared to a control group of randomly selected patients with diabetes who were prescribed non-glucagon-like peptide 1 (non-GLP-1) receptor agonist (RA) medications (174,584 patients in each group).

The researchers found that patients with diabetes taking semaglutide had an absence of NAION risk at the one-month, three-month, six-month, and one-year time points after the index date. However, at the two-year, three-year, and four-year time points from the index date, those taking semaglutide had an increased risk for NAION (hazard ratios, 2.39, 2.44, and 2.05, respectively). Patients with diabetes and concomitant hypertension who were taking semaglutide had an increased risk for NAION (hazard ratio, 2.42). Patients with diabetes who had a history of Ozempic use or stand-alone Ozempic prescription history also had increased NAION risk.

"Among patients with diabetes, an elevated risk of NAION was associated with semaglutide use compared with non-GLP-1 RA use," the authors write. "However, the study's retrospective design can only infer associations rather than establish causality."

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted April 2025

Read this next

Few Adolescents With Obesity Prescribed Obesity Medications

FRIDAY, June 13, 2025 -- Despite an increase in the prevalence of prescribing, only 0.5 percent of U.S. adolescents with obesity were prescribed an obesity medication in 2023...

Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials

THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...

Adherence to Healthy Diet Improves Cardiometabolic Risk, Even Without Weight Loss

WEDNESDAY, June 11, 2025 -- A healthy diet improves cardiometabolic risk factors, even if not associated with weight loss (WL), according to a study published online June 5...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.